Sai Life Sciences FY26 Revenue Up 29% to ₹2,192 Cr, Net Profit Doubles to ₹355 Cr
Sai Life Sciences reported a 29% YoY increase in FY26 revenue to ₹2,192 crore and a 109% YoY surge in net profit to ₹355 crore. EBITDA grew 56% YoY to ₹661 crore. The company incurred ₹633 crore in Capex. An earnings call is scheduled for May 15, 2026.
The substantial increase in revenue and net profit, coupled with positive commentary from the management regarding future growth and capabilities, suggests a high impact on investor perception and company valuation.
The company reported strong financial results with significant year-on-year growth in revenue, EBITDA, and net profit, indicating positive business performance and execution.
Sai Life Sciences Limited has announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant year-on-year growth, with revenue from operations increasing by 29% to ₹2,192 crore for the full fiscal year FY26, up from ₹1,695 crore in FY25. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a substantial rise of 56% to ₹661 crore in FY26, compared to ₹425 crore in FY25. Consequently, the company's Profit After Tax (PAT) more than doubled, growing by 109% to ₹355 crore in FY26, from ₹170 crore in FY25. The EBITDA margin improved to 30% in FY26 from 25% in FY25, and the PAT margin increased to 16% from 10%.
For the fourth quarter of FY26, revenue from operations stood at ₹602 crore, a 4% increase compared to ₹580 crore in the corresponding quarter of the previous year. EBITDA for Q4FY26 grew by 17% to ₹189 crore from ₹161 crore in Q4FY25, with the EBITDA margin rising to 31% from 28%. PAT for the quarter increased by 18% to ₹104 crore from ₹88 crore year-on-year. The company also incurred a capital expenditure (Capex) of ₹633 crore during FY26.
Mr. Krishna Kanumuri, Managing Director and CEO, highlighted that FY26 was an important year for deepening relationships with global pharma customers, expanding integrated CRDMO capabilities, and investing for future growth, noting the strong long-term fundamentals of innovation-led outsourcing and supply chain diversification. Mr. Siva Chittor, Chief Financial Officer, emphasized strong execution, healthy growth in revenues and EBITDA, and a continued focus on disciplined capital allocation and operational resilience.
Sai Life Sciences will conduct an earnings call on May 15, 2026, at 4:00 PM IST to discuss these financial and business performance results.
What to do with a filing like this
Sai Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Life Sciences Limited. Read the original for the full detail.